ODTX compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

ODTXOdyssey Therapeutics, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

ODTXOdyssey Therapeutics, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ODTX2 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—▼−9.60%—

Q2 FY26—▲+10.09%—

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedODTX realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedspan: ODTX 92d · AMGN 273dSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

ODTXOdyssey Therapeutics, Inc.

19.20▲+1.68%· post 19.20

Mkt cap$923.4MRevenue$99,000Q3 FY25Revenue—

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

ClosedNov 6 '26

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

ClosedNov 6 '26

ODTXOdyssey Therapeutics, Inc.

AMGNAmgen Inc

19.20▲+1.68%post 19.20

Price

460.55▲+0.06%post 460.42

$923.4M

Mkt cap

$249.0B

Q3 FY25$99,000

Revenue

$10.4BQ3 FY26

—

Revenue

$36.8BFY25

ODTX19.20▲+1.68%vsAMGN460.55▲+0.06%ClosedNov 6 '26